Oystershell has come to an agreement with Bayer HealthCare LLC to acquire RID®, one of the leading brands in lice treatment in the US. 

RID® is known for its strong consumer brand awareness, high levels of professional endorsement and its well-respected brand logo and attributes.  In 2019, RID® achieved 25 million USD in retail sales and is the #2 brand in the US lice treatment market.

Nuvo Pharmaceuticals announced that it had acquired the global rights for Resultz, a head lice treatment from Piedmont Pharmaceuticals.

TyraTech has reported an increase of 31% in sales during the first half of 2016.

Hatchtech is submitting its Xeglyze lice treatment to the FDA for approval and has signed a commercialisation agreement with Dr. Reddy’s.

Eden Research PLC has agreed a licensing deal with TerpeneTech Ltd granting exclusive use of its encapsulation technologies and other intellectual property for head lice treatments.

Tyratech have announced increased revenues for 2014, and are focussing more of their funding on Vamousse.

Larada Sciences Inc., a Utah-based head lice treatment company, have filed a complaint alleging patent infringement by Nitless Noggins, a California-based lice treatment company.

The patents concern methods for lice eradication via localised heat treatment, and are held by the University of Utah Research Federation, who have licensed them to Larada Sciences.

Larada Sciences developed AirAllé, a device for treating lice infection via heat treatment, which received FDA clearance in prior to its release with AirAllé branding in 2013.

Tyratech, Inc. has recently announced two further US distribution agreements for Vamousse, its lice treatment product.

Hatchtech recently announced plans to commercialise its Xeglyze lice treatment product, while Ego Pharmaceuticals expand their international distribution network.

Several head lice companies have recently released financial updates related to their head lice treatments.